incb099280
Small moleculeexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2020 (NCT04242199)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Merkel Cell · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- DNA Repair-Deficiency Disorders · Phase 1
- Esophageal Squamous Cell Carcinoma · Phase 1
- Healthy Volunteers · Phase 1
- Melanoma · Phase 1
- Mesothelioma · Phase 1
- Microsatellite Instability · Phase 1
- Nasopharyngeal Carcinoma · Phase 1
- Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06309394 | Phase 1 | May 15, 2024 | Incyte |
| NCT06337162 | Phase 1 | May 1, 2024 | Incyte, University of Pennsylvania |
| NCT06039384 | Phase 1 | Jan 10, 2024 | Incyte, Mirati Therapeutics Inc. |
| NCT05949632 | Phase 1/Phase 2 (Phase 2) | Dec 15, 2023 | Incyte |
| NCT05879822 | Phase 2 | Oct 30, 2023 | Incyte |
| NCT05888844 | Phase 2 | Oct 9, 2023 | Incyte |
| NCT05909995 | Phase 1 | Aug 29, 2023 | Incyte |
| NCT04242199 | Phase 1 | Apr 1, 2020 | Incyte |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Incyte | For profit | 8 | 7 | 2 | 2020 |
| Mirati Therapeutics Inc. | For profit | 1 | 0 | 1 | 2024 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1